Introduction
Type 2 diabetes (T2D), obesity, and metabolic disease impact over one billion people and present a challenge to public health and economic growth (1,S34) . In the United States, over 30 million people have diabetes and it is a leading cause of morbidity and mortality, especially through increased cardiovascular disease (CVD) (2) . The remission rate under usual care is 0.5 -2%(3) while intensive lifestyle intervention resulted in remission rates (both partial and complete) of 11.5% and 9.2% at 1 and 2 years (4) . When lifestyle intervention is insufficient, medications are indicated to manage the disease and slow progression.
When T2D care directed at disease reversal is successful, this includes achievement of restored metabolic health, glycemic control with reduced dependence on medication, and in some cases disease remission. Three non-pharmaceutical approaches have demonstrated high rates of at least temporary T2D diabetes reversal or remission: bariatric surgery, very low calorie diets (VLCD), and nutritional ketosis achieved through carbohydrate restriction (5, 6, 7) . In controlled clinical trials, each approach has demonstrated improved glycemic control and CVD risk factors, reduced pharmaceutical dependence, and weight loss. The three approaches show a similar time-course with glycemic control preceding weight loss by weeks or months, suggesting potential overlap of mechanisms(8,S35,S36).
With bariatric surgery, up to 60% of patients demonstrate T2D remission at 1 year (9) . Outcomes at two years and beyond indicate ~50% of patients can achieve ongoing diabetes remission(10,S37).
The second Diabetes Surgery Summit recommended using bariatric surgery to treat T2D with support from worldwide medical and scientific societies (10) , but both complications and cost limit its widespread use(11,S38). VLCDs providing <900 kcal/day allow rapid discontinuation of most medications, improved glycemic control, and weight loss. This approach is necessarily temporary, however, with weight regain and impaired glucose control typically occurring within 3-6 months of reintroduction of substantial proportions of dietary carbohydrate (6,12,S39,S40).
A third approach to diabetes reversal is sustained dietary carbohydrate restriction. Lowcarbohydrate diets have consistently elicited improvements in T2D, metabolic disease, and obesity up to one year(13,S41); however, longer-term studies and studies including patients prescribed insulin are limited. A low carbohydrate Mediterranean diet caused remission in 14.7% of newly diagnosed diabetes patients at 1 year versus 4.1% with a low-fat diet (14), and a small randomized trial utilizing a ketogenic diet demonstrated improved weight and diabetes control at one year (15). Systematic reviews also corroborate the effectiveness of a low-carbohydrate diet for T2D(16,S42) and it has recently become a consensus recommended dietary option(17). Nonetheless, sustained adherence is considered challenging(17), and an LDL-C increase is sometimes observed(18,S43,S44) with carbohydrate restriction. Given that total LDL-P, small LDL-P, and ApoB tend to improve or remain unchanged, the impact of an isolated increase in LDL-C on CVD risk in the context of this dietary pattern is unknown.
We have previously reported 1 year outcomes of an open-label, non-randomized, controlled, longitudinal study with 262 continuous care intervention (CCI) and 87 usual care (UC) participants with T2D(7). The CCI included telemedicine, health coaching, and guidance in nutritional ketosis using an individualized whole foods diet. Eighty-three percent of CCI participants remained enrolled 1 year and 60% of completers achieved an HbA1c <6.5% while prescribed metformin or no diabetes medication.
Weight was reduced and most CVD risk factors improved(19). Here we report the results of this study at 2 years. The primary aims were to investigate the effect of the CCI on retention, glycemic control, and weight. Secondary aims included: (1) investigating the effect of the CCI on bone mineral density, visceral fat composition, cardiovascular risk factors, liver, kidney, thyroid and inflammatory markers; diabetes medication use, and disease outcomes (e.g. diabetes remission, metabolic syndrome); and (2) comparing 2-year outcomes between the CCI and UC groups.
Materials and methods

Study design and participants
The comprehensive study design has been published previously (7, 25) , and the results presented here are the follow-up 2-year results ( (n=126, CCI-virtual). We also recruited another cohort of participants with T2D (n=87) who were categorized as usual care (UC). Exclusion criteria have been published previously (7, 25) . A brief description of the study participants and interventions (CCI and UC) are listed in the supplementary data (Methods section). All study participants provided written informed consent and the study was approved by the Franciscan Health Lafayette Institutional Review Board.
Outcomes
Primary Outcomes
The primary outcomes were retention, HbA1c, HOMA-IR-insulin and c-peptide derived (scores, equations in supplemental material A), fasting glucose, fasting insulin, c-peptide and weight.
Secondary Outcomes
Long-term body composition changes assessed in CCI participants included bone mineral density (BMD), abdominal fat content (CAF and A/G ratio), and lower extremities lean mss (LELM).
Body composition was not assessed in UC participants. Cardiovascular-, liver-, kidney-, thyroid-related and inflammatory markers were analyzed (Table 1 and Supplementary Table 1) . Changes in overall diabetes medication use, use by class, and insulin dose were tracked over the two years of the trial.
The prevalence of T2D (diabetes reversal, partial and complete remission), metabolic syndrome, suspected steatosis and absence of fibrosis were evaluated at 2 years in the CCI and UC groups using the criteria provided in Supplementary Table 2 (assignment references listed in the supplementary). Assignment of metabolic syndrome was based on the presence of three of the five defined criteria according to measured laboratory and anthropometric variables; pharmacological treatment for any of the conditions was not considered.
Adverse events encountered in the study were reported to the Principal Investigator and reviewed by the Institutional Review Board (IRB).
Laboratory and body composition measures
Clinical anthropometrics and laboratory blood analytes measurements were obtained at baseline, 1 year, and 2 years from the CCI and UC participants. Details of the methods were previously published (7, 19) . All blood analytes were measured at a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. The CCI participants were also assessed for total body composition changes at baseline, 1 and 2 years using dual X-ray absorptiometry (DXA) (Lunar GE Prodigy,
Madison, WI) and analyzed using GE Encore software(v11.10, Madison, WI). The details of the DXA procedure and analyses are listed in the supplementary data (Methods section).
Statistical analyses
All analyses were conducted using SPSS statistical software (Version 25.0, Armonk, NY). A detailed description of the statistical method is included in the supplementary data (Methods section). Briefly, we conducted intent-to-treat analyses to assess study outcomes. For continuous study outcomes, linear mixed-effects (LMM) models were used to assess within-group changes from baseline to 2 years and between-group differences at 2 years. For dichotomous disease outcomes, generalized estimating equation models were used. Changes in diabetes medication use and insulin dosage from baseline to 2 years were assessed using McNemar's tests with continuity correction when appropriate and paired t-tests. Available data only was used to assess changes in medication use, which was routinely adjusted as part of the intervention protocol. Data from the two CCI educational groups were combined because no group differences were found, as in our prior time points(7,S45).
Completers-only analyses were also conducted for all outcomes and results appear in the supplementary material. For all study analyses, nominal significance levels (P) are presented in the tables. A significance level of P<0.0012 ensures overall simultaneous significance of P<0.05 over the 43 variables using Bonferroni correction. Americans was higher in the CCI group. Baseline characteristics were well-matched between the groups, except for mean weight and BMI, which were higher in the CCI group. There were no significant differences between completers and dropouts on baseline characteristics for either group.
Results
Participant characteristics
Retention and long-term dietary adherence
One hundred ninety four participants (of 262; 74%) remained enrolled in the CCI at 2 years in the app at least once between 1 and 2 years.
All adjusted within and between group changes in study outcomes for the CCI and UC groups appear in Table 2 .
Glycemic outcomes
From baseline to 2 years (Table 2 ), significant reductions in HbA1c (0.9% unit decrease, -12% relative to baseline, P=1.8x10 -17 ; Figure 2A ), C-peptide (-27%, P=2.2x10 -16 ), fasting glucose (-18%, P=6.8x10 -9 ), fasting insulin (-42%, P=2.2x10 -18 , Figure 2B ), insulin-derived HOMA-IR excluding exogenous insulin users (-42%, P=2.7x10 -13 ), and C-peptide-derived HOMA-IR (-30%, P=1.1x10 -15 )
were observed in the CCI group, whereas no changes occurred in the UC group (Supplementary Figures 1A and 1B) ( Table 2 ). There were also significant between-group (CCI vs. UC) differences observed at 2 years in HbA1c, fasting glucose, fasting insulin, insulin-derived HOMA-IR excluding exogenous users, and C-peptide-derived HOMA-IR, with the CCI group having lower glycemic marker means ( Table 2 ).
Metabolic and body composition outcomes
At 2 years, mean weight change from baseline was -10% (P=8.8x10 -28 ; Figure 2C ) in the CCI group, whereas no change was observed in the UC group (Supplementary Figure 1C) . Among CCI patients, 74% had ≥ 5% weight loss compared to only 14% of UC patients (Supplementary Figure 2; completers analysis). Consistent with the weight loss observed, the CCI group had reductions in abdominal fat content, with decreases in CAF (-15%, P=1.6x10 -21 , Figure 2D ) and the A/G ratio (-6%, P=4.7x10 -8 ) from baseline to 2 years ( Table 2 ). The CCI group's total spine BMD remained unchanged from baseline to 2 years after correction for multiple comparisons ( Table 2 ). The changes in the average LELM in the CCI are included in the Table 2 , and further elaborated in the supplementary data (Discussion section).
Cardiovascular risk factor outcomes
Decreases in systolic (-4%, P= 2.4x10 -6 , Figure 2E ) and diastolic (-4%, P= 3.3x10 -5 , Figure 2F ) blood pressures and triglycerides (-22%, P=6.2x10 -9 ) were observed in the CCI but not UC group at 2 years ( Table 2 , Supplementary Figures 3A and 3B ). The CCI group's HDL-cholesterol (+19%, P= 2.7x10 -16 ) and LDL-cholesterol (+11%, P=1.1x10 -4 ) both increased from baseline to two years, whereas no changes were observed in the UC group (Table 2) . No changes in total cholesterol were observed in either the CCI or UC group. At 2 years, the CCI group had higher HDL-cholesterol, higher LDLcholesterol, and lower triglycerides than UC. No between-group differences were observed at 2 years for systolic or diastolic blood pressure or total cholesterol (Table 2) .
Liver-related outcomes
From baseline to 2 years, the CCI group's ALT (-21%, P=4.0x10 -10 ; were reduced, whereas no changes were observed in UC (e.g. ALT; Supplementary Figure 3C ; Table   2 ). No bonferroni-corrected group differences were observed for bilirubin,ALT, nor AST at 2 years (Table 2) .
Kidney, thyroid, and inflammation outcomes
The eGFR increased in the CCI (+3%, P=1.6x10 -4 , Table 2 ) but not UC group at 2 years. The UC but not CCI group had increased anion gap and decreased uric acid ( Table 2) . No bonferronicorrected within-group changes in BUN, serum creatinine, TSH, or Free T4 were observed in either the CCI or UC group from baseline to 2 years. No between-group differences were observed for any thyroid-or kidney-related markers at 2 years (Table 2) .
From baseline to 2 years, decreases in the CCI group's hsCRP (-37%, P=6.9x10 -13 , Table 2 , Figure 2H ) and white blood cell count (-7%, P=4.3x10 -5 ) were observed. No changes were observed in the UC group (Supplementary Figure 3D) . At 2 years, both markers of inflammation were lower in the CCI group compared to the UC group (Table 2) .
Diabetes Medication
All within-group changes in diabetes medication use among study completers appear in eTable 3 (ns are listed in the table). The proportion of CCI completers taking any diabetes medication (excluding metformin) decreased from 55.7% at baseline to 26.8% at 2 years (P=1.3x10 -11 , Figure 3A ).
Reductions in the use of diabetes medication classes included insulin (29.8% at baseline to 11.3% at 2 years, P=9.1x10 -9 ) and sulfonylureas (23.7% at baseline and 0% at 2 years, P=4.2x10 -12 ). At 2 years, no changes in the proportions of CCI completers taking SGLT-2 inhibitors (10.3% to 3.1%, P=0.01), DPP-4 (9.9% to 6.7%, P=0.42), GLP-1 agonists (13.4% to 10.8%, P=0.42), thiazolidinediones (1.5% to 2.6%, P=0.73), or metformin (71.4% to 63.9%, P=0.05) were observed after correction for multiple comparisons. No changes in use of any diabetes medication (excluding metformin) or individual diabetes medication classes were observed in the UC completers from baseline to 2 years. The mean dose for insulin-using participants at baseline decreased among CCI participants by 81% (P= 2.6x10 -12 ) at 2 years, but not in UC participants (+13%, P=0.45) (see Figure 3B ). For participants who remained insulin-users at 2 years, the mean dose also decreased in the CCI group by 61% (P=9.2x10 -5 ) but not UC group (+19%, P=0.29). Among participants prescribed each diabetes medication class, the proportion with each dosage change (eliminated, reduced, unchanged, increased, or newly added) at 2 years in each group appears in Figure 3C .
Disease Outcomes
All within-group changes and between-group differences in disease outcomes among the CCI and UC group participants appear in supplementary Table 4 (intent-to-treat analyses were conducted;
all below n=262). The proportion of participants meeting the defined criteria for diabetes reversal at 2 years increased 41.4% (from 12.1% at baseline to 53.5% at 2 years, P<0.0x10 -36 ) in the CCI group, whereas no Bonferroni-corrected change was observed in the UC group (7.1% absolute decrease, P=0.04). In addition, diabetes remission (partial or complete) was observed in 46 (17.6%) participants in the CCI group and two (2.4%) of the UC participants at 2 years. Complete remission was observed in 17 (6.7%) CCI participants and none (0%) of the UC participants at 2 years.
At 2 years, 27.2% of CCI participants and 6.5% of UC patients showed resolution of metabolic syndrome. The proportion of participants with metabolic syndrome decreased from baseline to 2 years in the CCI (from 89.1% to 61.9%, P= 4.9x10 -15 ) but not UC group. The two years improvements of suspected steatosis and fibrosis status are included in the supplementary Tables 4 and 5 .
Safety and adverse events
In the CCI group, there were no reported serious adverse events between one and two years attributed to the intervention or that resulted in discontinuation, including no reported episodes of ketoacidosis or severe hypoglycemia requiring assistance. Adverse events occurring in the first year of intervention (n=6) were previously reported [10] . Details of the adverse events are included in the supplementary data (Results section).
Discussion
Following 2 with this CCI is comparable to that observed in pharmaceutical trials, but is achieved while discontinuing 67.0% of diabetes-specific prescriptions including most insulin and all sulfonylureas that engender risks for weight gain and hypoglycemia(22,23). Comparable improvements in glycemic control and reduced medication were not observed in UC participants recruited from the same healthcare system, suggesting that the CCI improves diabetes management relative to usual care.
Other interventions using carbohydrate restriction reported variable long-term glycemic improvement outcomes(24-26,S49-S51). The 0.9% absolute (12% relative) HbA1c reduction observed at 2 years is consistent with low carbohydrate studies reporting HbA1c reductions of 8-15% at 2 to 3.5 years (25,26,S49,S51) with medication reduction. Two others studies reported no changes in HbA1c from baseline to 2 years, even though the low carbohydrate arm reduced HbA1c in the first 6 months(24,S50). This study observed a modest increase in HbA1c and weight between 1 and 2 years in CCI participants suggesting some reduction in long-term effectiveness. Interestingly, insulin-levels show no regression toward baseline from 1 to 2 years indicating long-term improvement in hyperinsulinemia, an important component of diabetes pathology (8, 27 This reveals an opportunity to increase adherence to nutritional ketosis for patients not achieving their desired health outcomes while prompting future research investigating the association between dietary adherence and health improvements.
A majority of the CCI participants (53.5%) met criteria for diabetes reversal at 2 years while 17.6% achieved diabetes remission (i.e. glycemic control without medication use) based on intent-totreat with multiple imputation. The percentage of all CCI enrollees (N=262) with verified reversal and remission requiring both completion of two years of the trial and an obtained laboratory value for HbA1c were 37.8% and 14.9%, respectively. CCI diabetes reversal exceeds remission as metformin prescriptions were usually continued given its role in preventing disease progression (7, 29) , preserving β -cell function (29) and in treatment of pre-diabetes per guidelines (28). Partial and complete remission rates of 2.4% and 0.2% per year, respectively, have been reported in 122,781 T2D patients receiving standard diabetes care(3).The two-year remission rate (both partial and complete) in the CCI (17.6%) is higher than that achieved through intensive lifestyle intervention (ILI) in the Look AHEAD trial (9.2%)(4).
Greater diabetes remission in the CCI versus Look AHEAD ILI could result from differences in the dietary intervention(14), patients' ability to self-select their lifestyle or effectiveness of continuous remote care. Length of time with a T2D diagnosis is a factor in remission, with longer time since diagnosis resulting in lower remission(3,4,6,S53). Despite a mean of 8.4 years since diagnosis among CCI participants, the remission rate was higher than the Look AHEAD trial where its participants had a median of 5 years(4) since diabetes diagnosis.
Participants in the CCI achieved 10% mean weight loss (-11.9kg) at 2 years. CCI weight loss was comparable to observed weight loss following surgical gastric banding (-10.7kg) at 2 years(29).
Previous studies consistently report that weight loss increases the likelihood of T2D remission (3, 4, 6) .
CCI participants also improved blood pressure, triglycerides, and HDL-cholesterol. Total cholesterol was unchanged and calculated LDL-cholesterol was increased at 2 years, but was not different from the LDL-cholesterol level observed at one year (+0.51, P=0.85). Despite the rise in LDL-cholesterol, the CCI cohort improved in 22 out of 26 CVD markers at one year(19). This includes a decrease in small LDL-particles and large VLDL-P and an increase in LDL-particle size with no changes in ApoB(19) 
Strengths and limitations
This study's strengths include its size and prospective, longitudinal data collection from two participant groups (CCI and UC) which allowed statistical analysis by LMMs to investigate intervention time and treatment effects. While not randomized, the participants' self-selection of intervention may contribute to the observed high retention and predicts real-life clinical management of chronic disease.
The study also included patients prescribed insulin and with long-standing disease, groups often excluded from prior studies. The multi-component aspect of the intervention involving regular biomarker monitoring and access to a a remote care team may have improved the patients' long-term dietary adherence and engagement. The dietary advice including encouraging participants to restrict carbohydrates, moderate protein intake, and eat to satiety may also help in maintaining long-term effectiveness. Weaknesses of this study include the lack of randomization and limited racial diversity.
Interpretation of DXA body composition was limited to subregion analyses due to to the scanner not accomodating the patients' complete body.
Conclusions
At 2 years, the CCI, including remote medical management with instruction in nutritional ketosis, led to improvements in blood glucose, insulin, HbA1c, weight, blood pressure, triglycerides, liver function, and inflammation and reduced dependence upon medication. These long-term benefits were achieved concurrent with reduced prevalence of metabolic syndrome and visceral adiposity. The CCI had no adverse effect on bone mineral density. The CCI group also had higher prevalence of diabetes reversal and remission compared to the UC group following a standard diabetes care program. These results provide strong evidence that sustained improvement in diabetes status can be achieved through the continuous remote monitoring and accountability mechanisms provided by this multi-component CCI including recommendations for low carbohydrate nutrition. 
